[{"id":"d1c3eacf-0328-4f81-84b9-3eec3754a13e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01902329","created_at":"2021-01-18T08:33:55.539Z","updated_at":"2024-07-02T16:37:15.071Z","phase":"Phase 1","brief_title":"A Safety Study of SGN-CD33A in AML Patients","source_id_and_acronym":"NCT01902329","lead_sponsor":"Seagen Inc.","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • vadastuximab talirine (SGN-CD33A)"],"overall_status":"Completed","enrollment":" Enrollment 195","initiation":"Initiation: 07/01/2013","start_date":" 07/01/2013","primary_txt":" Primary completion: 03/18/2016","primary_completion_date":" 03/18/2016","study_txt":" Completion: 12/08/2017","study_completion_date":" 12/08/2017","last_update_posted":"2018-01-05"}]